vs
CATALYST PHARMACEUTICALS, INC.（CPRX）とEcovyst Inc.（ECVT）の財務データ比較。上の社名をクリックして会社を切り替えられます
Ecovyst Inc.の直近四半期売上が大きい（$199.4M vs $152.6M、CATALYST PHARMACEUTICALS, INC.の約1.3倍）。Ecovyst Inc.の前年同期比売上増加率が高い（34.0% vs 7.6%）。CATALYST PHARMACEUTICALS, INC.の直近四半期フリーキャッシュフローが多い（$44.9M vs $22.9M）。過去8四半期でCATALYST PHARMACEUTICALS, INC.の売上複合成長率が高い（24.5% vs 18.7%）
Catalyst Pharmaceuticalsは米国フロリダ州コーラルゲーブルズに本拠を置くバイオ医薬品企業で、希少疾患向け治療薬の開発を事業の核心としています。主力品にランバート・イートン筋無力症候群（LEMS）治療薬のアミファンプリジンリン酸塩（商品名Firdapse）があり、2018年11月のFDA承認により、既存の成人に加え6歳以上の小児LEMS患者への投与も認められました。
Ecovyst Inc.は持続可能な特殊材料をグローバルに提供する企業で、高性能触媒と機能性添加剤の開発・製造を行っています。産業製造、消費財、環境保護などの分野の顧客に対し、業務効率化と炭素排出削減を支援するソリューションを提供しています。
CPRX vs ECVT — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $152.6M | $199.4M |
| 純利益 | $52.7M | — |
| 粗利率 | 82.9% | 23.4% |
| 営業利益率 | 40.5% | 10.9% |
| 純利益率 | 34.5% | — |
| 売上前年比 | 7.6% | 34.0% |
| 純利益前年比 | -5.8% | — |
| EPS（希薄化後） | $0.40 | $0.06 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $152.6M | $199.4M | ||
| Q3 25 | $148.4M | $204.9M | ||
| Q2 25 | $146.6M | $176.1M | ||
| Q1 25 | $141.4M | $143.1M | ||
| Q4 24 | $141.8M | $148.9M | ||
| Q3 24 | $128.7M | $153.9M | ||
| Q2 24 | $122.7M | $154.0M | ||
| Q1 24 | $98.5M | $141.6M |
| Q4 25 | $52.7M | — | ||
| Q3 25 | $52.8M | $-79.3M | ||
| Q2 25 | $52.1M | $6.0M | ||
| Q1 25 | $56.7M | $-3.6M | ||
| Q4 24 | $55.9M | — | ||
| Q3 24 | $43.9M | $14.3M | ||
| Q2 24 | $40.8M | $8.3M | ||
| Q1 24 | $23.3M | $1.2M |
| Q4 25 | 82.9% | 23.4% | ||
| Q3 25 | 84.7% | 25.4% | ||
| Q2 25 | 85.9% | 22.8% | ||
| Q1 25 | 87.3% | 13.3% | ||
| Q4 24 | 84.7% | 28.9% | ||
| Q3 24 | 85.0% | 29.3% | ||
| Q2 24 | 87.4% | 27.3% | ||
| Q1 24 | 87.3% | 23.5% |
| Q4 25 | 40.5% | 10.9% | ||
| Q3 25 | 44.7% | 13.8% | ||
| Q2 25 | 45.2% | 9.0% | ||
| Q1 25 | 44.8% | -0.7% | ||
| Q4 24 | 44.3% | 15.1% | ||
| Q3 24 | 39.6% | 17.9% | ||
| Q2 24 | 44.2% | 14.1% | ||
| Q1 24 | 27.5% | 9.5% |
| Q4 25 | 34.5% | — | ||
| Q3 25 | 35.6% | -38.7% | ||
| Q2 25 | 35.6% | 3.4% | ||
| Q1 25 | 40.1% | -2.5% | ||
| Q4 24 | 39.4% | — | ||
| Q3 24 | 34.1% | 9.3% | ||
| Q2 24 | 33.2% | 5.4% | ||
| Q1 24 | 23.6% | 0.9% |
| Q4 25 | $0.40 | $0.06 | ||
| Q3 25 | $0.42 | $-0.69 | ||
| Q2 25 | $0.41 | $0.05 | ||
| Q1 25 | $0.45 | $-0.03 | ||
| Q4 24 | $0.44 | $-0.26 | ||
| Q3 24 | $0.35 | $0.12 | ||
| Q2 24 | $0.33 | $0.07 | ||
| Q1 24 | $0.19 | $0.01 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $709.2M | $197.2M |
| 総負債低いほど良い | — | $392.6M |
| 株主資本純資産 | $954.3M | $603.4M |
| 総資産 | $1.1B | $1.3B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.65× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $709.2M | $197.2M | ||
| Q3 25 | $689.9M | $82.0M | ||
| Q2 25 | $652.8M | $69.6M | ||
| Q1 25 | $580.7M | $127.5M | ||
| Q4 24 | $517.6M | $131.4M | ||
| Q3 24 | $442.3M | $123.5M | ||
| Q2 24 | $375.7M | $83.3M | ||
| Q1 24 | $310.4M | $103.1M |
| Q4 25 | — | $392.6M | ||
| Q3 25 | — | $854.8M | ||
| Q2 25 | — | $856.6M | ||
| Q1 25 | — | $859.0M | ||
| Q4 24 | — | $860.8M | ||
| Q3 24 | — | $862.7M | ||
| Q2 24 | — | $862.4M | ||
| Q1 24 | — | $866.2M |
| Q4 25 | $954.3M | $603.4M | ||
| Q3 25 | $920.2M | $607.9M | ||
| Q2 25 | $856.0M | $692.4M | ||
| Q1 25 | $794.3M | $698.7M | ||
| Q4 24 | $727.6M | $700.5M | ||
| Q3 24 | $660.9M | $729.4M | ||
| Q2 24 | $608.7M | $717.3M | ||
| Q1 24 | $561.4M | $711.4M |
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.7B | ||
| Q2 25 | $971.9M | $1.8B | ||
| Q1 25 | $908.9M | $1.8B | ||
| Q4 24 | $851.4M | $1.8B | ||
| Q3 24 | $772.0M | $1.8B | ||
| Q2 24 | $706.4M | $1.8B | ||
| Q1 24 | $646.7M | $1.8B |
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | 1.41× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | — | 1.23× | ||
| Q4 24 | — | 1.23× | ||
| Q3 24 | — | 1.18× | ||
| Q2 24 | — | 1.20× | ||
| Q1 24 | — | 1.22× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $44.9M | $41.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $44.9M | $22.9M |
| FCFマージンFCF / 売上 | 29.4% | 11.5% |
| 設備投資強度設備投資 / 売上 | 0.0% | 9.4% |
| キャッシュ転換率営業CF / 純利益 | 0.85× | — |
| 直近12ヶ月FCF直近4四半期 | — | $69.9M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $44.9M | $41.8M | ||
| Q3 25 | $32.4M | $55.3M | ||
| Q2 25 | $71.3M | $33.0M | ||
| Q1 25 | $60.0M | $10.3M | ||
| Q4 24 | $70.9M | $43.5M | ||
| Q3 24 | $72.9M | $59.9M | ||
| Q2 24 | $64.1M | $10.0M | ||
| Q1 24 | $31.9M | $36.5M |
| Q4 25 | $44.9M | $22.9M | ||
| Q3 25 | — | $53.2M | ||
| Q2 25 | $71.3M | $7.8M | ||
| Q1 25 | — | $-14.0M | ||
| Q4 24 | $70.8M | $30.9M | ||
| Q3 24 | $72.6M | $53.6M | ||
| Q2 24 | $64.1M | $-9.3M | ||
| Q1 24 | $31.7M | $19.1M |
| Q4 25 | 29.4% | 11.5% | ||
| Q3 25 | — | 26.0% | ||
| Q2 25 | 48.6% | 4.4% | ||
| Q1 25 | — | -9.8% | ||
| Q4 24 | 49.9% | 20.7% | ||
| Q3 24 | 56.4% | 34.9% | ||
| Q2 24 | 52.3% | -6.1% | ||
| Q1 24 | 32.2% | 13.5% |
| Q4 25 | 0.0% | 9.4% | ||
| Q3 25 | 0.0% | 1.0% | ||
| Q2 25 | 0.0% | 14.4% | ||
| Q1 25 | 0.0% | 16.9% | ||
| Q4 24 | 0.1% | 8.5% | ||
| Q3 24 | 0.2% | 4.1% | ||
| Q2 24 | 0.0% | 12.5% | ||
| Q1 24 | 0.2% | 12.3% |
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 1.37× | 5.52× | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | 4.21× | ||
| Q2 24 | 1.57× | 1.20× | ||
| Q1 24 | 1.37× | 29.90× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
ECVT
| Industrial Mining Automotive | $101.3M | 51% |
| Regeneration And Treatment Services | $90.0M | 45% |
| Other | $8.1M | 4% |
